Study of lung cancer patients who got chemo-immunotherapy before planned surgery but didn't have surgery
Part of Cancer, Lungs & breathing clinical trials.
This study looks at patients with stage II or III non-small cell lung cancer who started chemotherapy plus immunotherapy before planned surgery but did not actually have surgery. It aims to understand why surgery was canceled and how patients did over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage II or III non-small cell lung cancer (based on tests like scans)
- You started chemotherapy plus immunotherapy as a first treatment, intending to have surgery later
- You received at least one cycle of this treatment
- You did not have surgery for at least six months after starting this treatment
- Your doctors have records of why surgery was canceled and how you are doing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a treatment given before surgery for non-small cell lung cancer. Patients receive chemotherapy plus immunotherapy (chemo-immunotherapy) first, then have surgery to remove the tumor. The goal is to see how well this approach works.
This study looks at a treatment plan that uses immunotherapy before and after surgery for non-small cell lung cancer. The goal is to see if this approach helps patients do better and to find out which patients benefit most.
This study tests a combination of an immunotherapy drug (sintilimab) and chemotherapy to see if it can shrink advanced lung cancer enough to make surgery possible. The goal is to improve outcomes for people whose cancer is currently too extensive for surgery.
This study tests whether doing surgery only after checking if the tumor shrinks with chemo-immunotherapy is safe and effective for people with locally advanced lung cancer. It may help avoid surgery if the cancer hasn't responded well.
This study looks at how well immunotherapy given before surgery works for non-small cell lung cancer. It aims to help doctors understand real-world outcomes for patients who receive this treatment.
Hear when a new Stage II-III Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.